Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentamidine Dosing for Cutaneous Leishmaniasis
NCT02919605Phase 2Completed
- Sponsor
- Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
- Start
- Jan 2014
- Primary completion
- Jan 2016
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of pentamidine in cutaneous leishmaniasis (CL) (3 arms), sponsored by Fundação de Medicina Tropical Dr. Heitor Vieira Dourado. Primary endpoint: Number of patients with reduction in 50% in the diameters of the ulcers and lesions skin at 2 months. Started Jan 2014; status: completed.
02
Drugs
pentamidine
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on NCT02919605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02919605.